SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 24, 2002; DOI 10.1182/blood-2002-01-0163. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-01-0163v1 100/6/2132    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Scheibenbogen, C. Articles by Keilholz, U. Search for Related Content PubMed PubMed Citation Articles by Scheibenbogen, C. Articles by Keilholz, U. Related Collections Immunobiology Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 September 2002, Vol. 100, No. 6, pp. 2132-2137 IMMUNOBIOLOGY CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia Carmen Scheibenbogen, Anne Letsch, Eckhard Thiel, Alexander Schmittel, Volker Mailaender, Steffi Baerwolf, Dirk Nagorsen, and Ulrich Keilholz From Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Universitätsklinikum Benjamin-Franklin, Freie Universität Berlin, Germany. Wilms tumor gene product WT1 and proteinase 3 are overexpressed antigens in acute myeloid leukemia (AML), against which cytotoxic T lymphocytes can be elicited in vitro and in murine models. We performed this study to investigate whether WT1- and proteinase 3-specific CD8 T cells spontaneously occur in AML patients. T cells recognizing HLA-A2.1-binding epitopes from WT1 or proteinase 3 could be detected ex vivo in 5 of 15 HLA-A2-positive AML patients by interferon- (IFN-) ELISPOT assay and flow cytometry for intracellular IFN- and in 3 additional patients by flow cytometry only. T cells producing IFN- in response to proteinase 3 were further characterized in one patient by 4-color flow cytometry, identifying them as CD3+CD8+CD45RA+ CCR7 T cells, resembling cytotoxic effector T cells. In line with this phenotype, most of the WT1- and proteinase-reactive T cells were granzyme B+. These results provide for the first time evidence for spontaneous T-cell reactivity against defined antigens in AML patients. These data therefore support the immunogenicity of WT1 and proteinase 3 in acute leukemia patients and the potential usefulness of these antigens for leukemia vaccines. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Rezvani, A. S. M. Yong, A. Tawab, B. Jafarpour, R. Eniafe, S. Mielke, B. N. Savani, K. Keyvanfar, Y. Li, R. Kurlander, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia Blood, March 5, 2009; 113(10): 2245 - 2255. [Abstract] [Full Text] [PDF] J. W. King, S. Thomas, F. Corsi, L. Gao, R. Dina, R. Gillmore, K. Pigott, A. Kaisary, H. J. Stauss, and J. Waxman IL15 Can Reverse the Unresponsiveness of Wilms' Tumor Antigen-Specific CTL in Patients with Prostate Cancer Clin. Cancer Res., February 15, 2009; 15(4): 1145 - 1154. [Abstract] [Full Text] [PDF] C. Chaise, S. L. Buchan, J. Rice, J. Marquet, H. Rouard, M. Kuentz, G. E. Vittes, V. Molinier-Frenkel, J.-P. Farcet, H. J. Stauss, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance Blood, October 1, 2008; 112(7): 2956 - 2964. [Abstract] [Full Text] [PDF] C. I-U. Chen, H. T. Maecker, and P. P. Lee Development and dynamics of robust T-cell responses to CML under imatinib treatment Blood, June 1, 2008; 111(11): 5342 - 5349. [Abstract] [Full Text] [PDF] M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses Blood, February 1, 2008; 111(3): 1357 - 1365. [Abstract] [Full Text] [PDF] A. J. Barrett Leukemia Vaccines to Boost the Graft-versus-Leukemia Effect after Allogeneic Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 330 - 333. [Abstract] [Full Text] [PDF] K. Rezvani, A. S. M. Yong, S. Mielke, B. N. Savani, L. Musse, J. Superata, B. Jafarpour, C. Boss, and A. J. Barrett Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies Blood, January 1, 2008; 111(1): 236 - 242. [Abstract] [Full Text] [PDF] K. Rezvani, A. S. M. Yong, B. N. Savani, S. Mielke, K. Keyvanfar, E. Gostick, D. A. Price, D. C. Douek, and A. J. Barrett Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia Blood, September 15, 2007; 110(6): 1924 - 1932. [Abstract] [Full Text] [PDF] A. M. Asemissen, U. Keilholz, S. Tenzer, M. Muller, S. Walter, S. Stevanovic, H. Schild, A. Letsch, E. Thiel, H.-G. Rammensee, et al. Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1 Clin. Cancer Res., December 15, 2006; 12(24): 7476 - 7482. [Abstract] [Full Text] [PDF] J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches Blood, December 15, 2006; 108(13): 4109 - 4117. [Abstract] [Full Text] [PDF] M. Brune, S. Castaigne, J. Catalano, K. Gehlsen, A. D. Ho, W.-K. Hofmann, D. E. Hogge, B. Nilsson, R. Or, A. I. Romero, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood, July 1, 2006; 108(1): 88 - 96. [Abstract] [Full Text] [PDF] F. B. Thoren, A. I. Romero, and K. Hellstrand Oxygen Radicals Induce Poly(ADP-Ribose) Polymerase-Dependent Cell Death in Cytotoxic Lymphocytes. J. Immunol., June 15, 2006; 176(12): 7301 - 7307. [Abstract] [Full Text] [PDF] F. Grunebach, V. Mirakaj, V. Mirakaj, M. R. Muller, T. Brummendorf, and P. Brossart BCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia Cancer Res., June 1, 2006; 66(11): 5892 - 5900. [Abstract] [Full Text] [PDF] J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin. Cancer Res., May 1, 2006; 66(9): 4913 - 4921. [Abstract] [Full Text] [PDF] U. Keilholz, P. Martus, and C. Scheibenbogen Immune monitoring of T-cell responses in cancer vaccine development. Clin. Cancer Res., April 1, 2006; 12(7): 2346s - 2352s. [Abstract] [Full Text] [PDF] R. Gillmore, S.-A. Xue, A. Holler, J. Kaeda, D. Hadjiminas, V. Healy, R. Dina, S. C. Parry, I. Bellantuono, Y. Ghani, et al. Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer Clin. Cancer Res., January 1, 2006; 12(1): 34 - 42. [Abstract] [Full Text] [PDF] K. Rezvani, J. M. Brenchley, D. A. Price, Y. Kilical, E. Gostick, A. K. Sewell, J. Li, S. Mielke, D. C. Douek, and A. J. Barrett T-Cell Responses Directed against Multiple HLA-A*0201-Restricted Epitopes Derived from Wilms' Tumor 1 Protein in Patients with Leukemia and Healthy Donors: Identification, Quantification, and Characterization Clin. Cancer Res., December 15, 2005; 11(24): 8799 - 8807. [Abstract] [Full Text] [PDF] J. Greiner, L. Li, M. Ringhoffer, T. F. E. Barth, K. Giannopoulos, P. Guillaume, G. Ritter, M. Wiesneth, H. Dohner, and M. Schmitt Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia Blood, August 1, 2005; 106(3): 938 - 945. [Abstract] [Full Text] [PDF] M. Gannage, M. Abel, A.-S. Michallet, S. Delluc, M. Lambert, S. Giraudier, R. Kratzer, G. Niedermann, L. Saveanu, F. Guilhot, et al. Ex Vivo Characterization of Multiepitopic Tumor-Specific CD8 T Cells in Patients with Chronic Myeloid Leukemia: Implications for Vaccine Development and Adoptive Cellular Immunotherapy J. Immunol., June 15, 2005; 174(12): 8210 - 8218. [Abstract] [Full Text] [PDF] E. S. Doubrovina, M. M. Doubrovin, S. Lee, J.-H. Shieh, G. Heller, E. Pamer, and R. J. O'Reilly In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity Clin. Cancer Res., November 1, 2004; 10(21): 7207 - 7219. [Abstract] [Full Text] [PDF] Y. Oka, A. Tsuboi, T. Taguchi, T. Osaki, T. Kyo, H. Nakajima, O. A. Elisseeva, Y. Oji, M. Kawakami, K. Ikegame, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression PNAS, September 21, 2004; 101(38): 13885 - 13890. [Abstract] [Full Text] [PDF] P. Savage, L. Gao, K. Vento, P. Cowburn, S. Man, N. Steven, G. Ogg, A. McMichael, A. Epenetos, E. Goulmy, et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen Blood, June 15, 2004; 103(12): 4613 - 4615. [Abstract] [Full Text] [PDF] K. Rezvani, M. Grube, J. M. Brenchley, G. Sconocchia, H. Fujiwara, D. A. Price, E. Gostick, K. Yamada, J. Melenhorst, R. Childs, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation Blood, October 15, 2003; 102(8): 2892 - 2900. [Abstract] [Full Text] [PDF] D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz Natural T Cell Immunity against Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4296 - 4303. [Abstract] [Full Text] [PDF] P. J. Amrolia, G. Muccioli-Casadei, E. Yvon, H. Huls, U. Sili, E. D. Wieder, C. Bollard, J. Michalek, V. Ghetie, H. E. Heslop, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses Blood, September 15, 2003; 102(6): 2292 - 2299. [Abstract] [Full Text] [PDF] H. E. Heslop, F. K. Stevenson, and J. J. Molldrem Immunotherapy of Hematologic Malignancy Hematology, January 1, 2003; 2003(1): 331 - 349. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020